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Introduction
Proton pump inhibitors (PPIs) are one group of drugs 
that inhibit gastric acid secretion by binding irreversibly 
to the gastric proton pump. They include several different 
agents, such as omeprazole, pantoprazole, lansoprazole, 
deslansoprazole, etc. They are used in treatment of 
conditions such as duodenal and gastric ulcer, Zollinger-
Ellison syndrome, gastro-esophageal reflux disease, 
Barrett’s esophagus and Helicobacter pylori infection of the 
upper gastro-intestinal tract. They are firstly introduced 
in the late 1980s (1). According to the U.S. Food and Drug 
Administration (FDA), about 21 million people have 
consumed one prescription of PPIs in the United States in 
2009 (2). All PPIs possess a common mechanism of action 
for reducing parietal cell acid production by blocking 
gastric hydrogen potassium ATPase (1).
The PPIs are known as one group of drugs that are well-
tolerated in healthy subjects and where serious harms are 
rare (2).  In fact, the exposure to PPIs for kidney injury 
is not established yet, but there are several evidences that 
adumbrate on PPIs administration. The recent reports 
show an association between long-term prescription of 
PPIs and the appearance of adverse effects, for example; 
hyper-secretion of gastric acid after their withdrawal 
(3), with bone fracture (4) and low levels of magnesium 
in blood (5). Also, reducing the benefits of anti-platelet 
agents such as clopidogrel in patients with acute coronary 
syndromes, is followed by the inhibition of hepatic 
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Proton pump inhibitors (PPIs) are one group of drugs that inhibit gastric acid secretion by 
binding irreversibly to the gastric proton pump. This paper aimed to review the impact of 
PPIs on kidney function and structure by presenting the updated information in this regard. 
In this review, we summarize in electronic databases including Google Scholar, EMBASE, 
MEDLINE, Scopus and EBSCO during the period of 1980 to 2017 by using the following 
search terms; proton-pump inhibitors, kidney injury, renal diseases, adverse events of proton-
pump inhibitors, acute interstitial nephritis, renal injury and chronic kidney disease. The PPIs 
are known as one group of drugs that are well tolerated in healthy subjects and where serious 
harms are rare. The some reports reveal that long-term administration of PPIs is associated 
with adverse effects such as: increasing the incident risk of kidney injury, hyper-secretion 
of gastric acid after their withdrawal, bone fracture, decreased levels of blood magnesium, 
interaction with metabolism of antiplatelet agents, increased risk of enteric infections and 
community-acquired pneumonia.
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enzymes, which account for the metabolism of antiplatelet 
agents (6). PPIs have also been linked to increased risk of 
enteric infections such as clostridium difficile-associated 
diarrhea (7) and community-acquired pneumonia (8).
On the other hand, according to a case-control over the 
10-year period, the peptic ulcer disease incidence was 
about 10–12 times higher in patients with chronic kidney 
disease (CKD) than in those without CKD especially 
in elderly CKD patients (9). In addition, it was pointed 
out that, some factors such as hemodialysis therapy and 
administration of ulcerogenic medications (nonsteroidal 
anti-inflammatory drugs, aspirin and clopidogrel) may 
further increase peptic ulcer risk in CKD patients (6,9). 
Hence, CKD is a strong risk factor for peptic ulcer 
disease(10).
Recently much attention has been directed to consider 
the probable association between exposure to PPIs and an 
increase in the incidence of kidney injury (10). 
This paper aimed to review the impact of PPIs on 
kidney function and structure by presenting the updated 
information in this regard.
Materials and Methods
For this review, we searched in electronic databases 
including Google Scholar, EMBASE, MEDLINE, Scopus 
and EBSCO during the period of 1980 to 2017 by using the 
following search terms; proton-pump inhibitors, kidney 
injury, renal diseases, adverse events of proton-pump 
inhibitors, acute interstitial nephritis, renal injury and 
chronic kidney disease. We used review articles, clinical 
trials, cohort studies, case-control studies and case reports 
that were relevant to our topic.
Potential risk of kidney injury after administration of 
PPIs
Acute interstitial nephritis (AIN) is an important form 
of nephritis changing the interstitium of the kidneys 
around the tubules resulting in acute renal failure from 
immune-mediated tubulointerstitial injury (9,10). Drugs 
commonly induce AIN thought an idiosyncratic and cell-
mediated immunologic reaction (10). Some case reports 
suggest that AIN, which is induced by PPIs, eventually 
leads to acute renal failure. The patients who presented 
weight loss, nausea, vomiting and a rise in serum 
creatinine concentration after the administration of PPIs, 
were diagnosed by renal biopsy (11,12).
According to a case serious study, PPIs were a common 
identified cause of AIN in the Auckland area where 
even incomplete recovery occurred after withdrawal of 
the drug. Elevated erythrocyte sedimentation rate and 
C-reactive protein may be an alarm for clinicians on the 
onset of renal failure (12).
A case control study showed that the incidence of renal 
disease was two times more in patients using PPIs 
compared to those who did not use PIPs. This quasi-
experimental design supported an association between 
renal injury with PPIs exposure which imply considering 
and controlling of different aspects of kidney disease 
following PPI administration (13).
In a cohort study, Antoniou et al compared the risk of 
acute kidney injury and AIN in older patients taking PPIs 
with patients not using these drugs. They found a raised 
risk of AKI due to AIN following PPI administration in 
older individuals (14).
Chronic kidney disease is a process of worsening the kidney 
function over months or years without specific symptoms 
(9). It can associate with an increased risk of death and 
cardiovascular events. The risk factors of chronic kidney 
disease are not fully described yet. However, diabetes 
mellitus, hypertension and some medications can be 
potential factors to increase the prevalence of chronic 
kidney disease. Recently, a cohort study explained the 
association between PPI exposure and the increase of 
incident kidney disease in general population which leads 
to the idea that PPI administration is an independent risk 
factor for chronic kidney disease in addition to AKI (15). 
More recently, a systematic review showed that, interstitial 
nephritis is responsible for approximately 15% of acute 
renal failure cases after PPI exposure with the mean 
duration about 13 weeks in the absence of baseline renal 
failure. They detected nephritis following measurement of 
serum creatinine and conducting renal biopsy. All patients 
recovered in an average time of 35.5 weeks. Only one case 
needed to permanent dialysis. There were no reports of 
death (16).
The effects of PPIs are dependent on the transport of protons. 
They inhibit acid secretion by irreversibly blocking the 
hydrogen/potassium adenosine triphosphatase enzyme 
system of the gastric parietal cells (1). Vacuolar protons 
adenosine triphosphatase are multi-subunit complexes 
that mediate the adenosine triphosphate-dependent 
transport of protons. They are located in the kidney 
medulla and osteoclast-containing medullary bone that 
may be inhibited by PPIs (1,11).
Overall, the association of acute kidney injury and this 
group of drugs may be overstated by considering the low 
risk of recurrence. However, kidney injury should be 
considered as a high index of suspicion in renal failure 
patients taking  PPIs.
Potential risk of hypomagnesemia by PPIs
Magnesium homeostasis is usually related to intestinal 
absorption, renal excretion and exchanging with bone. 
Hypomagnesemia is usually associated with hypocalcemia, 
hypokalemia and hypoparathyroidism. The first report was 
in 2006, regarding two hypomagnesemia cases associated 
with the administration of proton-pump inhibitors which 
were presented with carpopedal spasm due to severe 
hypomagnesemia and hypocalcemia accompanied with 
lacking appropriate rise in serum levels of parathyroid 
hormone (15).
The prevalence of PPI-induced hypomagnesaemia is not 
exactly known. In fact, they represented the tip of an 
iceberg in patients with hypomagnesaemia related to PPI 
administration. A systematic review and meta-analysis 
study showed that PPI therapy for one year or more 
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can lead to severe and symptomatic hypomagnesemia 
particularly in patients ranged between 50 and 80 years 
(5). In addition, this type of hypomagnesemia often 
occurred with low or normal parathyroid hormone 
levels, calcium levels in blood of <2.20 mmol/L and 
blood potassium level below 3.50 mmol/L. As regards, 
there was not an association between the proportion of 
hypomagnesemia with the degree of hypokalemia or 
hypocalcemia. Sometimes, it was seen in accompaniment 
thiazide or loop diuretic administration, alcohol abuse, 
poor renal function or small bowel resection. However, 
it was resolved when PPI therapy was withdrawn but 
recurred when PPI administration was started again even 
with another PPI (5). In contrast, Markovits et al did 
not find any association between magnesium levels and 
histamine type-2 receptor antagonists (17).
Hypomagnesemia associated-PPI administration may lead 
to severe symptoms such as tetany, seizures, convulsions, 
cardiac arrhythmia. The molecular, physiological factors, 
risk factors and mechanisms that may be involved in 
the association between hypomagnesemia and PPI are 
not exactly understood (17). There are some hypotheses 
that PPI administration may reduce the intestinal 
absorption of magnesium throughout an effect on tight 
junction function directly of gatekeeper of transepithelial 
magnesium ion transport-transient receptor potential 
Melastatin 6 (TRPM6) or as a result of intestinal pH 
changes (18). A study suggested that genetic factors might 
increase susceptibility to PPI-induced hypomagnesemia 
in patients with TRPM6 mutations (19).
However, hypomagnesaemia symptoms are non-specific 
or may be misinterpreted. Also measurements of serum 
magnesium are not checked as a routine biochemical 
profile. So, it is better that indications for continuing 
PPI therapy in patients are kept under regular review, 
for example patients on non-steroidal anti-inflammatory 
drugs. Nevertheless, if PPI therapy is necessitated for 
long time, the serum magnesium should be measured 
regularly at least in patients with symptoms or signs of 
magnesium deficiency, concurrently use other decrescent 
agents for magnesium level or poor renal function. When 
hypomagnesemia secondary to PPI therapy is recognized, 
the PPI then switches to a histamine type-2 receptor 
antagonist. Prescription of magnesium supplements may 
be helpful.
Potential risk of infections
There are several reports concerning the potential risk 
of critical infections among individuals treated with PPI 
agents. In PPI users, enteric infections such as clostridium 
difficile colitis (7,20) and pulmonary infection (8) could 
be particularly frequent. The mechanisms underlying 
predisposition of infections associated to PPI exposure 
are not exactly clear (1). Gastric acid that is secreted by 
the parietal cells in the stomach, has an important role 
in the inhibition of ingested organisms and bacterial 
pathogens (7). PPIs agents can impair overthrow of 
ingested microorganisms due to selectively suppression 
gastric acid. On the other hand, researchers have pointed 
to potential drug-induced disorders on the bactericidal 
capacity of leukocytes (3). 
Clostridium difficile is the main infectious agent which 
leads to antibiotic associated-diarrhea and hospital-
acquired infections. The several published articles have 
shown an increased risk of clostridium difficile infection 
with different durations of PPI therapy as well as enteric 
infections with Shigella, Salmonella, campylobacter 
and listeria in hospitalized patients (7). In addition, an 
increased risk of clostridium difficile infection in non-
hospitalized patients on PPIs therapy occurs. Recently, a 
multi-country study, confirmed the association between 
PPI exposure and clostridium difficile infections across 
Australia, Korea, Taiwan, Japan and Canada (20). 
Overall, PPI therapy within a short course may be useful 
in selected patients. Accordingly, it should be discontinued 
in asymptomatic patients or in patients having the risk 
factors on gut flora. It is better that patients on PPIs be 
aware on infection susceptibility particularly on bacterial 
diarrhea. They should also learn to exercise care on intake 
of higher risk diets such as raw and unpasteurized foods 
especially during living in tropical area or traveling to 
tropical regions of the developing world. Even it may be 
considered to the administration of chemoprophylaxis 
drugs to prevent this illness in PPI users.
A systematic review demonstrated a 1.5-time 
increased risk of community acquired pneumonia with 
outpatient PPI therapy plus a 1.6-fold increased risk for 
hospitalization with community acquired pneumonia (8). 
While PPI administration may cause community acquired 
pneumonia both through acute pH dysregulation as well 
as altering respiratory flora and micro-aspiration of the 
change of the gut flora (8). However, the pathophysiologic 
mechanisms of association between community acquired 
pneumonia and PPI exposure is not clarify known and it is 
necessary to conduct further studies. It is better to consider 
risks and benefits before prescription of PPIs and increase 
knowledge on this risk factor for adults presenting with 
pneumonia. 
Potential risk of other adverse events
There are some reports that PPIs may interact with anti-
platelet agents in patients with acute coronary syndrome 
(6). The mechanism of this effect is unknown. In fact, 
PPIs can inhibit the hepatic enzyme (CYP2C19) which is 
needed for activation of clopidogrel (21). Dimethylarginine 
dimethylaminohydrolase is an enzyme that is found 
in all mammalian cells. It degrades methylarginines, 
specifically asymmetric dimethylarginine and NG-
monomethyl-L-arginine. Asymmetric dimethylarginine is 
an endogenous inhibitor of nitric oxide synthase. Plasma 
levels of asymmetric dimethylarginine are correlated 
with increased risk for cardiovascular disease, likely 
owing to its attenuation of the vasoprotective effects of 
endothelial nitric oxide synthase. PPIs also inhibit the 
activity of dimethylarginine dimethylamino hydrolase 
that metabolizes asymmetric dimethylarginine then 
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competitive inhibitor of endothelial nitric oxide synthase 
(3,6,10). The proses lead to raise the risk of vascular 
inflammation and thrombosis due to increase oxidative 
stress (6). 
There are not clear guidelines for PPIs prescription 
in patients under treatment with antiplatelet agents 
particularly newer agents. But it is necessary to more 
clinician’s attention and aware on especial conditions such 
as acute coronary syndrome or cerebrovascular accident 
and also to evaluate as an individual basis about risks and 
benefits of concomitant therapy with antiplatelet agents 
and PPIs.
Several studies have showed an increased risk in hip, 
spine, wrist and other site fractures especially in patients 
who have taken PPIs for longer than one year duration (4). 
The electrolyte disturbance and vitamin deficiency were 
aggravating factors for this adverse events. PPIs inhibit 
intra-gastric secretion of hydrochloric acid that facilitates 
calcium absorption thought small intestinal. On the other 
hand, osteoclasts have proton pumps, therefore PPIs can 
potentially directly effect on calcium absorption thought 
small intestinal and reducing bone resorption of calcium 
(4,22). Malabsorption of vitamin B12 (cobalamin) and 
other nutrient elements were observed in the patients with 
atrophic gastritis or achlorhydria (22). It may be happened 
due to diminution in upper small intestine gastric acid, 
bacterial overgrowth and increase bacterial consumption 
of cobalamin. It is possible that, PPIs exposure influence 
the malabsorption of vitamin B12 but is not prove yet. 
Hence, assessment for vitamin B12 deficiency in patients 
on PPI therapy is seldom recommended (23). In addition, 
iron absorption related to gastric acid secretion was 
been detected. Infect, long term PPI therapy may cause 
iron malabsorption due to the risk of achlorhydria and 
gastric acid hypo-secretion, although this matter did not 
demonstrate significant yet  (23). There is not approval 
to monitor patients on PPI therapy for iron deficiency 
anemia.
While there is not sufficient evidence to be certain on 
a causal relationship these adverse effects with PPIs 
administration, however, it needs to level elevation 
of clinical suspicion. Furthermore, clinicians should 
be aware on risk factors some such as age of patients, 
frail individuals and malnourishment particularly in 
chronically hospitalized patients to assess benefits of 
therapy against risks. Large randomized and prospective 
trials may also show or establish direct cause and effect 
associations between PPIs and adverse events.
Conclusion
Although, PPI agents have improvements in treatment 
of upper GI tract disorders, they are not without risk of 
adverse effects. The results of this review support the 
association between PPI use and renal disease and kidney 
injury, which are important implications for public health. 
These adverse effects may not be easily attributed to the 
treatment of PPIs and are often reverse and rarely life-
threatening. Hence, it is necessary that the awareness of 
physicians and pharmacists is increased to the recognition 
of the patient’s complaints and the clinical manifestations 
of these potentially harmful events, particularly in the 
first weeks after the initiation of the treatment by PPIs. In 
fact, more prescriptions of PPIs should not be clinically 
indicated, hence clinicians should monitor patients and 
stop the indiscriminate use of these drugs. In addition, 
it is necessary that more research is conducted on the 
underlying mechanisms of this association. 
Furthermore, non-pharmacological proceedings such as 
attentive observation, life style modification (for example 
weight reduction, stress reduction, eating smaller meals 
well before sleep and smoking cessation) may be useful 
and substitute in dyspepsia resolve. 
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